Répertoire des programmes destinés à améliorer la santé dans le monde – Sélection de programmes e-santé et m-santé

Statement 6 Nov 2024

IFPMA-INTERFARMA-FIFARMA statement on the Rio de Janeiro Declaration of the G20 Health Ministers

The innovative pharmaceutical industry, represented by IFPMA, INTERFARMA and FIFARMA reiterates its commitment to the G20 health priorities, reaffirmed in the Rio de Janeiro Declaration.

WHO EMRO RC71: Regional flagship initiative 1: Expanding equitable access to medical products

On 14 October 2024 in Doha, Qatar, IFPMA delivered a statement at the 71st session of the WHO EMRO Regional Committee on the Regional flagship initiative 1: Expanding equitable access to medical products.

The Value of Reference Agency Assessment Reports in Enabling Regulatory Reliance

Access to information, including the assessment documents of reference national regulatory agencies (NRA), is a key enabler of regulatory risk-based decision making. It promotes an understanding of what was reviewed by the reference NRA, provides a rationale for decision making and promotes confidence and trust. The Centre for Innovation in Regulatory Science (CIRS) has published...